Pharmaco
Report
How your body processes medications. Key drug-metabolism genes with CPIC Level A clinical action guidance — the report your physician needs before writing your next prescription.
⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.
See a fully rendered example — real RSIDs, peer-reviewed citations, and clinical action guidance — before you commit.
RSIDs analyzed in this panel
Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.
Supporting literature
CPIC Statin/SLCO1B1 Guideline v3.0 (Oct 2025 update) · cpicpgx.org. SEARCH Collaborative Group NEJM 2008 (SLCO1B1 rs4149056 · myopathy OR=4.5 heterozygous, OR=17 homozygous). PharmGKB CYP2D6/CYP2C19 Level 1A annotations. DPYD CPIC Level A (5-FU toxicity).
Why pharmacogenomics matters
An estimated 1 in 5 people carry a pharmacogenomic variant that significantly alters how they process a commonly prescribed medication. CYP2D6 poor metabolizers accumulate toxic drug levels at standard doses. SLCO1B1 intermediate carriers face a 4.5× increased myopathy risk with simvastatin. These interactions are preventable — with the right information shared with the right physician.
CPIC Level A — the highest clinical evidence tier
AuraGen PGx reports follow Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines — the international gold standard for translating genotype to prescribing recommendations. Level A means the evidence is sufficient to require clinical action. SLCO1B1 rs4149056 plus simvastatin is one of the most clinically proven pharmacogenomic interactions in medicine.
This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com
- ✓CYP2D6 · CYP2C19 · CYP3A4/5 · CYP2C9 — the four major metabolizing CYPs
- ✓SLCO1B1 — statin myopathy risk (CPIC Level A · highest evidence tier)
- ✓VKORC1/CYP2C9 — warfarin and anticoagulant sensitivity
- ✓DPYD — 5-fluorouracil chemotherapy toxicity safety
- ✓TPMT/NUDT15 — thiopurine myelosuppression risk
- ✓Physician-formatted PGx summary letter included
⚠ Research Use Only · Not FDA cleared